Supercharged immune cells take on Hard-to-Treat pancreatic cancer
Disease control
Recruiting now
This early-stage trial tests a new therapy that takes a patient's own immune T-cells, engineers them to recognize and attack pancreatic cancer cells with specific KRAS mutations, and infuses them back. The study includes 96 adults with advanced pancreatic cancer who have the righ…
Phase: PHASE1, PHASE2 • Sponsor: Anocca AB • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC